Neurocrine [NBIX] vs Zoetis [ZTS] Detailed Stock Comparison

Neurocrine Biosciences Inc.

NASDAQ
Loading...

Zoetis Inc.

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Neurocrine Biosciences Inc. wins in 9 metrics, Zoetis Inc. wins in 11 metrics, with 0 ties. Zoetis Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Neurocrine Biosciences Inc. Zoetis Inc. Better
P/E Ratio (TTM) 27.88 19.58 Zoetis Inc.
Price-to-Book Ratio 4.01 15.04 Neurocrine Biosciences Inc.
Debt-to-Equity Ratio 14.49 279.59 Neurocrine Biosciences Inc.
PEG Ratio 0.56 2.81 Neurocrine Biosciences Inc.
EV/EBITDA 18.09 13.96 Zoetis Inc.
Profit Margin (TTM) 16.73% 28.24% Zoetis Inc.
Operating Margin (TTM) 28.21% 34.69% Zoetis Inc.
EBITDA Margin (TTM) 28.21% 34.69% Zoetis Inc.
Return on Equity 16.38% 65.99% Zoetis Inc.
Return on Assets (TTM) 9.53% 15.26% Zoetis Inc.
Free Cash Flow (TTM) $748.70M $2.28B Zoetis Inc.
Dividend Yield N/A 1.21% N/A
1-Year Return 28.43% -51.58% Neurocrine Biosciences Inc.
Price-to-Sales Ratio (TTM) 4.58 5.26 Neurocrine Biosciences Inc.
Enterprise Value $12.06B $56.75B Zoetis Inc.
EV/Revenue Ratio 4.22 6.00 Neurocrine Biosciences Inc.
Gross Profit Margin (TTM) 97.82% 70.17% Neurocrine Biosciences Inc.
Revenue per Share (TTM) $29 $21 Neurocrine Biosciences Inc.
Earnings per Share (Diluted) $4.67 $6.02 Zoetis Inc.
Beta (Stock Volatility) 0.35 0.97 Neurocrine Biosciences Inc.
Short % of Float 5.90% 4.06% Zoetis Inc.

Neurocrine Biosciences Inc. vs Zoetis Inc. Stock Performance Analysis

Loading Price Chart...

NBIX
ZTS

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Neurocrine Biosciences Inc.-0.16%-2.21%0.69%22.84%3.54%13.45%
Zoetis Inc.1.51%0.16%3.42%-31.08%-32.94%-36.81%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Neurocrine Biosciences Inc.28.43%63.69%58.93%261.12%2,094.51%952.44%
Zoetis Inc.-51.58%-53.40%-57.08%71.34%156.59%156.59%

Performance & Financial Health Analysis: Neurocrine Biosciences Inc. vs Zoetis Inc.

MetricNBIXZTS
Market Information
Market Cap i$13.09B$49.75B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i1,084,1342,727,710
90 Day Avg. Volume i1,073,0653,835,940
Last Close$159.51$167.10
52 Week Range$122.14 - $169.57$139.70 - $200.33
% from 52W High-5.93%-16.59%
All-Time High$169.57 (Jun 04, 2026)$249.27 (Dec 27, 2021)
% from All-Time High-5.93%-32.96%
Growth Metrics
Quarterly Revenue Growth0.28%0.03%
Quarterly Earnings Growth0.49%0.04%
Financial Health
Profit Margin (TTM) i0.17%0.28%
Operating Margin (TTM) i0.28%0.35%
Return on Equity (TTM) i0.16%0.66%
Debt to Equity (MRQ) i14.49279.59
Cash & Liquidity
Book Value per Share (MRQ)$32.50$7.84
Cash per Share (MRQ)$14.75$5.48
Operating Cash Flow (TTM) i$782.70M$2.90B
Levered Free Cash Flow (TTM) i$397.81M$1.79B
Dividends
Last 12-Month Dividend Yield iN/A1.21%
Last 12-Month Dividend iN/A$2.03

Valuation & Enterprise Metrics Analysis: Neurocrine Biosciences Inc. vs Zoetis Inc.

MetricNBIX (Apr 24, 2026)ZTS (Apr 13, 2026)
Price Ratios
P/E Ratio (TTM) i27.8819.58
Forward P/E i14.6715.61
PEG Ratio i0.562.81
Price to Sales (TTM) i4.585.26
Price to Book (MRQ) i4.0115.04
Market Capitalization
Market Capitalization i$13.09B$49.75B
Enterprise Value i$12.06B$56.75B
Enterprise Value Metrics
Enterprise to Revenue i4.226.00
Enterprise to EBITDA i18.0913.96
Risk & Other Metrics
Beta i0.350.97
Book Value per Share (MRQ) i$32.50$7.84

Financial Statements Comparison: Neurocrine Biosciences Inc. vs Zoetis Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricNBIX (2025)ZTS (2025)
Revenue/Sales i2.86B9.47B
Cost of Goods Sold i52.10M2.67B
COGS % of Revenue i1.8%28.2%
Gross Profit i2.81B6.80B
Gross Margin i98.2%71.8%
Research & Development i1.02B698.00M
Operating Income (EBIT) i636.50M3.60B
Operating Margin i22.3%38.0%
EBITDA i688.00M4.17B
EBITDA Margin i24.1%44.1%
Pre-Tax Income i705.40M3.36B
Pre-Tax Income % of Revenue i24.7%35.5%
Income Tax i226.80M687.00M
Income Tax % of Revenue i7.9%7.3%
Net Income (Profit) i478.60M2.67B
Profit Margin i16.7%28.2%

Balance Sheet & Liquidity Metrics

MetricNBIX (2025)ZTS (2025)
Cash & Equivalents i713.00M2.31B
Total Current Assets i2.52B6.77B
Total Current Assets % of Revenue i88.2%71.5%
Total Current Liabilities i743.40M2.24B
Total Current Liabilities % of Revenue i26.0%23.6%
Long-Term Debt i415.30M9.24B
Long-Term Debt % of Revenue i14.5%97.6%
Total Shareholders Equity i3.25B3.33B
Retained Earnings i447.70M13.74B
Retained Earnings % of Revenue i15.7%145.2%
Property, Plant & Equipment i578.70M288.00M

Cash Flow Statement Comparison

MetricNBIX (2025)ZTS (2025)
Operating Cash Flow i617.80M2.78B
Operating Cash Flow % of Revenue i21.6%29.3%
Capital Expenditures iN/AN/A
Free Cash Flow i748.70M2.28B
FCF Margin i26.2%24.1%
Debt Repayment i0-1.35B
Common Stock Repurchase i-167.70M-3.24B

Short Interest & Institutional Ownership Analysis

MetricNBIXZTS
Shares Short i4.56M15.12M
Short Ratio i4.773.60
Short % of Float i5.90%4.06%
Shares Outstanding i100.10M424.93M
Float Shares i99.07M421.29M
% Held by Insiders i1.10%0.15%
% Held by Institutions i101.35%101.50%
% Held by Public i-2.45%-1.65%

Dividend Analysis & Yield Comparison: Neurocrine Biosciences Inc. vs Zoetis Inc.

MetricNBIXZTS
Last 12-Month Dividend iN/A$2.03
Last 12-Month Dividend Yield iN/A1.21%
3-Year Avg Annual Dividend iN/A$1.80
3-Year Avg Dividend Yield iN/A0.29%
3-Year Total Dividends iN/A$5.39
Ex-Dividend DateN/AJan 20, 2026